Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients

Cancer

Volumn 82, Issue 7, 1998, Pages 1260-1267

  Jin no, Kenji ^a   Tanimizu, Masahito ^a   Hyodo, Ichinosuke ^a   Nishikawa, Yoshiyuki ^a   Hosokawa, Yasushi ^a   Endo, Hisashi ^a   Doi, Toshihiko ^a   Mandai, Koichi ^a   Ishitsuka, Hideo ^b  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Angiogenic factor; Hepatocellular; Immunohistology; Platelet derived endothelial cell growth factor; Tumor marker

Indexed keywords

ANGIOGENIC FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SEQUENCE; ANGIOGENESIS; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOLOGY; LIVER CELL CARCINOMA; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; STROMA CELL;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; THYMIDINE PHOSPHORYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032055807     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980401)82:7<1260::AID-CNCR8>3.0.CO;2-J     Document Type: Article

References (23)

1. Klagsbrun M, Sasse J, Sullivan R, Smith JA. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci USA 1986;83:2448-52.
2. Barrette P, Travers M, Luqmani Y, Coombes RC. Transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 1990;61:612-7.
3. Schrieber AB, Winkler ME, Derynck R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 1986;232:1250-3.
4. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045-9.
5. Ishikawa F, Miyazono K, Hillman U, Drexler H, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-62.
6. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, et al. Angiogenic factor. Nature 1992; 356:668.
7. Miyadera KJ, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55:1687-90.
8. Folkman J, Shing Y. Angiogenesis. J Biol Hematol 1992; 267:10931-4.
9. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994;86:1234-8.
10. Heldin NE, Usuki K, Bergh J, Westermark B, Heldin CH. Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell line. Br J Cancer 1993;68:708-11.
11. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang S-M, Ogawa M, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996;73:884-8.
12. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 1995;176: 183-90.
13. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor β 1 in patients with hepatocellular carcinoma. Cancer 1994;73:2275-9.
14. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor β 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
15. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821-6.
16. Fujimoto K, Ichimori Y, Yamaguchi H, Arai K, Futami T, Ozono S, et al. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 1995;86:182-6.
17. Jin-no K, Tanimizu M, Hyodo I, Kurimoto H, Yamashita T. The plasma basic fibroblast growth factor increase with progression of chronic liver disease. J Gastroenterol 1997; 32:119-21.
18. Pauly JL, Schuller MG, Zelcer AA, Kirss TA, Gore SS, Germain MJ. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients: brief communication. J Natl Cancer Inst 1977;58: 1587-90.
19. Pauly JL, Paolini NS, Ebarb RL, Germain MJ. Elevated thymidine phosphorylase activity in the plasma and ascitic fluids of tumor-bearing animals (40034). Proc Soc Exp Biol Med 1978;157:262-7.
20. International Union Against Cancer. UICC TNM classification of malignant tumors. 4th edition. Geneva: International Union Against Cancer, 1987.
21. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissue. Biol Pharm Bull 1996;19:1407-11.
22. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963;44:239-42.
23. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 1996;32A:1227-32.